rawfin.tv
Gilead's Livdelzi Normalizes PBC Marker in Phase 3 Study
Marketsstocks🟠 Score 8AI Generated

Gilead's Livdelzi Normalizes PBC Marker in Phase 3 Study

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Gilead Sciences reported interim Phase 3 ASSURE study data indicating its liver drug Livdelzi (seladelpar) normalized a key PBC marker. These positive results could advance the drug's development and potential market entry.

Gilead SciencesPharmaceuticalsClinical TrialsDrug Development

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks